Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient
09 juin 2022 12h53 HE
|
Tiziana Life Sciences Ltd.
Zacks Small-Cap Research Note By John D. Vandermosten, CFA NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second...
Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient
09 juin 2022 12h25 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug...
Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient
09 juin 2022 12h04 HE
|
Tiziana Life Sciences Ltd.
Research Note Clinical Results for Second SPMS Patient NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
09 juin 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab
08 juin 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
A second patient also showed clinical improvements in the Positron Emission Tomography (PET) imaging analysis, neurologic exam, and in the Timed 25-Foot Walk test, following three months of treatment....
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs
06 juin 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies...
Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting
01 juin 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance
24 mai 2022 17h56 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
26 avr. 2022 11h43 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing alternative routes of...
FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab
05 avr. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
This Intermediate-Size Patient Population Expanded Access program will follow the same clinical dosing regimen as the two ongoing single-patient expanded access programs in SPMS patients.Tiziana...